Advicenne signs a partnership with Taïba Healthcare to market Sibnayal in the Middle East


Advicenne is expanding the availability of Sibnayal, its main drug. It will now be marketed in many countries in the Middle East, which has many cases of distal renal tubular acidosis. French will receive revenues significantly higher than 50% of future sales.

|  Photo credit: Shutterstock

| Photo credit: Shutterstock

The pharmaceutical company Advicenne, specialist in the development and marketing of treatments for rare kidney diseases, has just inaugurated a new partnership with Taïba Healthcare, a pharmaceutical laboratory in the Sultanate of Oman. With this agreement, Advicenne will be able to distribute its drug Sibnayal in many countries in the Middle East: Saudi Arabia, Sultanate of Oman, United Arab Emirates, Qatar, Kuwait and Bahrain.

Sibnayal is the main drug of Advicenne. It was approved in 2021 on the European and UK markets for the treatment of distal renal tubular acidosis (dRT). Today, the drug is in advanced clinical development in the United States and Canada. This is therefore the first marketing of the drug outside of Europe.

Developing international opportunities

The prevalence of distal renal tubular acidosis is among the highest in the world in the Gulf countries. Advicenne and Taïba will both be in charge of product registration at the local level and the latter will have exclusive marketing rights for Sibnayal in the territories mentioned. In return, Advicenne will receive revenues significantly higher than 50% of future sales (transfer price and royalties).

Advicenne thus pursues its objective of expanding the availability of Sibnayal internationally. Its managing director, Didier Laurens, declared that these agreements make ” proof of our desire to make Sibnayal available to as many patients as possible and to meet a medical need that is still poorly covered “.


VM




Source link -91